The virologist, who also coordinates the BMBF consortium of the German Federal Ministry of Education and Research, noted, “This project is a prime example of translational research from the university, which has found its way into the hospital in cooperation with industry.”
In December 2010, Jörn Möller and Alexander Alexandrov founded MYR Pharmaceuticals in partnership with the licensor Heidelberg University Hospital, where the active substance bulevirtide, which forms the basis of the drug, was developed by the molecular biologist Prof. The approval was the reward for ten years of hard work. “We succeeded in driving a life-saving drug to market – and providing patients with a treatment option for the most severe form of viral hepatitis.” “This was a very emotional moment for us,” says Florian Vogel now. With it, the world’s first active ingredient for the treatment of chronic hepatitis D is approved before the end of the third phase of the clinical trials. The European Medicines Agency has granted conditional approval to the drug Hepcludex. Corks are popping at the headquarters of the biotech company MYR GmbH on Thomasstraße in Bad Homburg.
0 kommentar(er)
